Involvement of endotoxin in the mortality of mice with gut-derived sepsis due to methicillin-resistant staphylococcus aureus

Microbiology and Immunology

Volumn 54, Issue 6, 2010, Pages 330-337

  Uramatsu, Masashi ^a   Matsumoto, Tetsuya ^b   Tateda, Kazuhiro ^c   Shibuya, Kazutoshi ^d   Miyazaki, Shuichi ^c   Horino, Tetsuya ^c   Tanabe, Masaaki ^c   Sumiyama, Yoshinobu ^a   Kusachi, Shinya ^a   Yamaguchi, Keizo ^c  

^a TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

Escherichia coli; Methicillin resistant staphylococcus aureus (MRSA); Mouse; Sepsis

Indexed keywords

AMPICILLIN; CEFTAZIDIME; CYCLOPHOSPHAMIDE; CYTOKINE; ESCHERICHIA COLI ENDOTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; CONTROLLED STUDY; DETERIORATION; ENDOTOXIN DETECTION; FECES CULTURE; FEMALE; INTESTINE INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; SEPSIS;

ANIMALS; BACTEREMIA; COLONY COUNT, MICROBIAL; FEMALE; INTESTINE, LARGE; LIPOPOLYSACCHARIDES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED BALB C; STAPHYLOCOCCAL INFECTIONS; SURVIVAL RATE;

ESCHERICHIA COLI; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUS;

EID: 77953597939     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2010.00217.x     Document Type: Article

References (34)

1. Rogers R.L., Perkins J. (2006) Skin and soft tissue infections. J Prim Care 33: 697-710.
2. Barie P.S. (1998) Antibiotic-resistant gram-positive cocci: Implication for surgical practice. World J Surg 22: 118-26.
3. Kusachi S., Yoshinobu S., Jiro N., Kunihiko K., Yoichi A., Yuichi Y., Hirohisa K., Yoshihisa S., Yoichi N. (1999) New method of control against postoperative methicillin-resistant Staphylococcus aureus infection. Surg Today 29: 724-9.
4. Cosgrove S.E., Qi Y., Kaye K.S., Harbath S., Karchmer A.W., Carmeli Y. (2005) The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcome: mortality, length of stay, and hospital charge. Infect Control Hosp Epidemiol 26: 166-74.
5. Gould I.M. (2007) MRSA bacteremia. Int J Antimicrob Agents 30(suppl.): S66-S70.
6. del Rio A., Cervera C., Moreno A., Moreillon P., Miŕo J.M. (2009) Patients at risk of complications of Staphylococcus aureus bloodstream infection. Clin Infect Dis 15(suppl.): S246-S253.
7. Sawai T., Tomono K., Yanagihara K., Yamamoto Y., Kaku M., Hirakata Y., Koga H., Tashiro T., Kohno S. (1997) Role of coagulase in a murine model of hematogenous pulmonary infection induced by intravenous injection of Staphylococcus aureus enmeshed in agar beads. Infect Immun 65: 466-71.
8. Patel M.V., De Souza N.J., Gupte S.V., Jafri M.A., Bhagwat S.S., Chugh Y., Khorakiwala H.F., Jacobs M.R., Appelbaum P.C. (2004) Antistaphylococcal activity ofWCK 771, a tricyclic fluoroquinolone, in animal infection models. Antimicrob Agents Chemother 48: 4754-61.
9. Reyes N., Skinner R., Benton B.M., Krause K.M., Shelton J., Obedencio G.P., Hegde S.S. (2006) Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 58: 462-65.
10. Stoff J.A., Nix D.E., DeYoung D.W. (2006) A pilot study of an anti-MRSA bio-engineered lacteal complex (anti-MRSA BLC) in a murine septicemia model. Immunopharmacol Immunotoxicol 28: 601-7.
11. Paulus S.C., van Saene H.K., Hemsworth S., Hughes J., Ng A., Pizer B.L. (2005) A prospective study of septicaemia on a paediatric oncology unit: a three-year experience at The Royal Liverpool Children's Hospital, Alder Hey, UK. Eur J Cancer 41: 2132-40.
12. Klastersky J. (1990) Chemoprophylaxis of gram-negative infections in neutropenic patients. Eur Urol 17(suppl.): 40-5.
13. Nakamura Y., Aramaki Y., Kakiuchi T. (2001) A mouse model for postoperative fatal enteritis due to Staphylococcus infection. J Surg Res 96: 35.
14. Tanaka H., Miyazaki S., Sumiyama Y., Kakiuchi T. (2004) Role of macrophages in a mouse model of postoperative MRSA enteritis. J Surg Res 118: 114-21.
15. Neu H.C. (1990) Pathophysiologic basis for the use of third-generation cephalosporins. Am J Med 88: 3S-11S.
16. Chamberland S., L'Ecuyer J., Lessard C., Bernier M., Provencher P., Bergeron M.G. (1992) Antibiotic susceptibility profiles of 941 gram-negative bacteria isolated from septicemic patients throughout Canada. The Canadian Study Group. Clin Infect Dis 15: 615-28.
17. Briñas L., Moreno M.A., Teshager T., Zarazaga M., Sáenz Y., Porrero C., Dominguez L., Torres C. (2003) Beta-lactamase characterization in Escherichia coli isolates with diminished susceptibility or resistance to extended-spectrum cephalosporins recovered from sick animals in Spain. Microb Drug Resist 9: 201-9.
18. Matsumoto T., Tateda K., Miyazaki S., Furuya N., Ohno A., Ishii Y., Hirakata Y., Yamaguchi K. (1999) Paradoxical synergistic effects of tumour necrosis factor and interleukin 1 in murine gut-derived sepsis with Pseudomonas aeruginosa. Cytokine 11: 366-72.
19. Howarth G.S., Tooley K.L., Davidson G.P., Butler R.N. (2006) A non-invasive method for detection of intestinal mucositis induced by different classes of chemotherapy drugs in the rat. Cancer Biol Ther 5: 1189-95.
20. Bone R.C., Balk R.A., Cerra F.B., Dellinger R.P., Fein A.M., Knaus W.A., Schein R.M., Sibbald W.J. (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101: 1644-55.
21. Berg R.D., Garlington A.W. (1979) Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun 23: 403-11.
22. Placencia F.X., Kong L., Weisman L.E. (2009) Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin. Pediatr Res 65: 420-4.
23. Kokai-Kun J.F., Chanturiya T., Mond J.J. (2007) Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model. J Antimicrob Chemother 60: 1051-9.
24. Bauumann H., Gauldie J. (1994) Acute phase response. Immunol Today 15: 74-80.
25. Parrillo J.E., Parker M.M., Natanson C., Suffredini A.F., Danner R.L., Cunnion R.E., Ognibene F.P. (1990) Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann InternMed 113: 227-42.
26. Casey L.C., Balk R.A., Bone R.C. (1993) Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann InternMed 15: 771-8.
27. Fisher C.J., Jr., Slotman G.J., Opal S.M., Pribble J.P., Bone R.C., Emmanuel G., Ng D., Bloedow D.C., Catalano M.A.; IL-1RA Sepsis Syndrome Study Group. (1994) Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 22: 12-21.
28. Fisher C.J., Jr., Opal S.M., Dhainaut J.F., Stephens S., Zimmerman J.L., Nightingale P., Harris S.J., Schein R.M., Panacek E.A., Vincent J.L., Foulke G.A., Warren E.L., Garrard C., Park G., Bodmer M.W., Cohen J., Van Der Linden C., Cross A.S., Sadoff J.C.; The CB0006 Sepsis Syndrome Study Group. (1993) Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 21: 318-27.
29. Damas P., Ledoux D., Nys M., Vrindts Y., De Groote D., Franchimont P., Lamy M. (1992) Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 215: 356-62.
30. Simon G.L., Gorbach S.L. (1984) Intestinal flora in health and disease. Gastroenterology 86: 174-93.
31. Wells C.L., Maddaus M.A., Simmons R.L. (1988) Proposed mechanisms for the translocation of intestinal bacteria. Rev Infect Dis 10: 958-79.
32. Deitch E.A., Berg R., Specian R. (1987) Endotoxin promotes the translocation of bacteria from the gut. Arch Surg 122: 185-90.
33. Billiar T.R., Maddaus M.A., West M.A., Curran R.D., Wells C.A., Simmons R.L. (1988) Intestinal gram-negative bacterial overgrowth in vivo augments the in vitro response of Kupffer cells to endotoxin. Ann Surg 208: 532-40.
34. Tateda K., Matsumoto T., Miyazaki S., Yamaguchi K. (1996) Lipopolysaccharide-induced lethality and cytokine production in aged mice. Infect Immun 64: 769-74.